Evercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $25 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- Bausch + Lomb Explores Potential Sale Amid Rumors
- Bausch + Lomb reinstated with an Underperform at BofA
- Bausch Health says Bausch + Lomb sale exploration process ‘ongoing’
- Bausch + Lomb responds to rumors of potential sale
- Bausch + Lomb falls -13.3%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
